GlassScriptPhysician profile
Raymond A Rubin
NPI 1033113691
$61,138.44
in general payments reported to CMS, 2019-2025
21 companies · $44.59 in 2025
The $44.59 reported for 2025 was less than what a typical Transplant Hepatology provider received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $12K · 2021: $7,807 · 2022: $17K · 2023: $7,761 · 2024: $43.13 · 2025: $44.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,440 · Food and Beverage: $349 · Travel and Lodging: $40.61 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,440.00 |
| Food and Beverage | $348.51 |
| Travel and Lodging | $40.61 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $33,711.65 | 2020-2023 | Terlivaz |
| Intercept Pharmaceuticals, INC. | $12,739.65 | 2019-2024 | Ocaliva |
| Mallinckrodt Enterprises LLC | $7,973.47 | 2019 | |
| Wilson Cook Medical Incorporated | $5,500.00 | 2021-2022 | |
| Boston Scientific Corporation | $466.80 | 2020-2022 | |
| Gilead Sciences, INC. | $158.57 | 2019-2025 | |
| Tela Bio, INC. | $149.36 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.07 | 2019-2023 | Xifaxan |
| Astellas Pharma US INC | $100.23 | 2022-2023 | Cresemba |
| Intra-Sana Laboratories | $52.45 | 2022 | |
| Baxter Healthcare | $41.79 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.48 | 2019 | |
| Abbvie INC. | $24.12 | 2022 | |
| Madrigal Pharmaceuticals | $21.53 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $21.27 | 2023 | Ultomiris |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $20.00 | 2024 | Iqirvo, Bylvay |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.